RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER

Abstract

In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence. Solifenacin 10 mg also decreased the frequency of nocturia. Solifenacin therapy was associated with a favorable tolerability profile and a low incidence of dry mouth, especially at the 5 mg starting dose.